Journal
JOURNAL OF NERVOUS AND MENTAL DISEASE
Volume 199, Issue 10, Pages 807-810Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/NMD.0b013e31822fcbe2
Keywords
Major depressive disorder; citalopram; social adjustment
Categories
Funding
- NIMH [N01 MH-90003]
- National Institutes of Health
- Centers for Disease Control
- Kaplen Foundation
- Massachusetts General Hospital
- Massachusetts General Hospital Physicians Organization
- AstraZeneca
- Bristol-Meyers Squibb
- Cephalon
- Janssen
- Lilly
- Merck
- Pfizer
- Wyeth
- Eli Lilly
- Abbott
- Alkermes
- Aspect Medical Systems
- Forest Laboratories
- GlaxoSmithKline
- Johnson Johnson
- Lichtwer Pharma GmbH
- Lorex Pharmaceuticals
- Novartis
- Organon
- Pamlab
- Pharmavite
- Roche
- Sanofi-Synthelabo
- Solvay
- Cyberonic Inc
- ImaRx Therapeutics, Inc
- Bristol-Myers Squibb Company
- Case-Western University
- Singapore Clinical Research Institute
- Agency for Healthcare Research and Quality (AHRQ)
- Corcept Therapeutics Inc
- Cyberonics Inc
- National Alliance for Research in Schizophrenia and Depression
- NIMH
- National Institute on Drug Abuse
- Pharmacia Upjohn
- Predix Pharmaceuticals (Epix)
- Solvay Pharmaceuticals Inc
- Targacept
- Best Practices
- American Foundation of Suicide Prevention
- ANT North America Inc (Advanced Neuro Technology)
- Abbott Laboratories
- Alkermes Inc
- BioResearch
- BrainCells Inc
- Cephalon Inc
- Clinical Trials Solutions LLC
- Covidien
- Eli Lilly and Company
- EnVivo Pharmaceuticals Inc
- Forest Pharmaceuticals Inc
- Ganeden Biotech Inc
- Johnson & Johnson Pharmaceutical Research Development
- Novartis AG
- Organon Pharmaceuticals
- PamLab LLC
- Pfizer Inc
- Pharmavite LLC
- RTC Logic LLC
- Sanofi-Aventis US LLC
- Shire
- Synthelabo
- Wyeth-Ayerst Laboratories
- Affectis Pharmaceuticals AG
- Amarin Pharma Inc
- Auspex Pharmaceuticals
- Bayer AG
- Best Practice Project Management Inc
- BioMarin Pharmaceuticals Inc
- Biovail Corporation
- CeNeRx Bio-Pharma
- CNS Response Inc
- Compellis Pharmaceuticals
- Cypress Pharmaceutical Inc
- Dov Pharmaceuticals Inc
- Eisai Inc
- EPIX Pharmaceuticals Inc
- Euthymics Bioscience Inc
- Fabre-Kramer Pharmaceuticals Inc
- GenOmind LLC
- Gruenthal GmbH
- Janssen Pharmaceutica
- Jazz Pharmaceuticals Inc
- Johnson & Johnson Pharmaceutical Research & Development LLC.
- Knoll Pharmaceuticals Corp.
- Labopharm Inc
- Lundbeck Inc
- MedAvante In
- Merck Co. Inc
- Methylation Sciences
- Neuronetics Inc
- Nutrition 21
- PharmaStar
- Precision Human Biolaboratory
- Prexa Pharmaceuticals Inc
- PsychoGenics
- Psylin Neurosciences Inc
- Ridge Diagnostics Inc
- RCT Logic LLC
- Sanofi-Aventis US LLC.
- Sepracor Inc
- Schering-Plough Corporation
- Somaxon Pharmaceuticals Inc
- Somerset Pharmaceuticals Inc
- Takeda Pharmaceutical Company Limited
- Tetragenex Pharmaceuticals Inc
- TransForm Pharmaceuticals Inc
- Transcept Pharmaceuticals Inc
- Vanda Pharmaceuticals Inc
- Adamed Co
- Advanced Meeting Partners
- American Psychiatric Association
- American Society of Clinical Psychopharmacology
- Belvoir Media Group
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb
- Imedex LLC
- MGH Psychiatry Reed/Primedia
- MGH Psychiatry Academy/Reed Elsevier
- United BioSource Corp
Ask authors/readers for more resources
Major depressive disorder (MDD) profoundly affects social functioning, including the ability to enjoy social activities with peers, friends, and family members. We sought to compare changes in social functioning and depressive symptoms in the first level of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Adult outpatients (N = 2876) with diagnoses of MDD were treated using flexible doses of citalopram for up to 14 weeks. We compared the change over the course of treatment in the social activities item of the Work and Social Adjustment Scale to the change in individual items of the Quick Inventory of Depressive Symptoms-Self-Rated (QIDS-SR). Improvement in social functioning was modestly positively correlated with improvement in sad mood, concentration/decision making, involvement, and energy/fatigability. Only 16% to 22% of the variance in the change in social functioning was accounted for by these symptoms, and only 32% was accounted for by the total QIDS-SR score. In this large real-world sample of outpatients treated using citalopram, changes in depressive symptoms do not entirely explain improvements in social functioning.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available